1-20 of 152
David H. Vesole
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702

Rahul Banerjee, Amber R. Fritz, Othman S. Akhtar, Ciara Louise Freeman, Andrew J. Cowan, Nina Shah, Heather J. Landau, Shaji Kumar, Dan T. Vogl, Yvonne A. Efebera, Philip L. McCarthy, David H. Vesole, Adam Mendizabal, Amrita Y Krishnan, George Somlo, Edward A. Stadtmauer, Marcelo C. Pasquini
Journal: Blood
Blood (2024) 144 (Supplement 1): 81.
https://doi.org/10.1182/blood-2024-199615
Published: 2024
Journal Articles

Potential Role of Donor CD3 Chimerism in Predicting Relapse after Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia (AML)

Maciej Kabat, Vanisha Patel, Sukhdeep Kaur, Michael Pelliccia, Charles Zhao, Patrick Roney, Alexandra Della Pia, Jaeil Ahn, David H. Vesole, Michele L. Donato, Hyung C Suh, Christina Cho, Pritish K. Bhattacharyya, Scott D Rowley, Andrew Ip
Journal: Blood
Blood (2024) 144 (Supplement 1): 7413.
https://doi.org/10.1182/blood-2024-204093
Published: 2024
Journal Articles

Real World Outcomes of Multiple Myeloma Patients Who Underwent Apheresis for Planned Chimeric Antigen Receptor (CAR) T Cell Therapy: A Single Center Experience

Ayrton I Bangolo, Sarvarinder Kaur Gill, Behzad Amoozgar, Shraboni Dey, Ronit Slotky, David S. Siegel, Harsh Parmar, Noa Biran, David H. Vesole, Pooja Phull
Journal: Blood
Blood (2024) 144 (Supplement 1): 7097.
https://doi.org/10.1182/blood-2024-211895
Published: 2024
Journal Articles

A Phase 2b Study of Selinexor in Combination with Pomalidomide in Patients with Pomalidomide-Refractory Multiple Myeloma

Noa Biran, David H. Vesole, Harsh Parmar, Pooja Phull, Kimberly R. Doucette, Rena Feinman, Xue Geng, Jaeil Ahn, Joshua Zenreich, Palka Anand, Kristin Ivanovski, Monique Pace, Alexandra Della Pia, Bianca DeAgresta, Lisa Biamonte, Martha Campanaro, Trina McClendon, Samanta BaboolallAracena, Adolfo Aleman, Ella Rutanen, Marie Layton, Genevieve Breeze, Aimee Chappell, Susan Kumka, David S. Siegel
Journal: Blood
Blood (2024) 144 (Supplement 1): 7070.
https://doi.org/10.1182/blood-2024-208473
Published: 2024
Journal Articles

Real World Outcomes with Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody: A Single Center Experience for Relapsed/ Refractory Multiple Myeloma (RRMM)

Sarvarinder Kaur Gill, Erika Fleming, Helen Gebre, Ayrton I Bangolo, David S. Siegel, David H. Vesole, Noa Biran, Harsh Parmar, Pooja Phull
Journal: Blood
Blood (2024) 144 (Supplement 1): 7047.
https://doi.org/10.1182/blood-2024-210350
Published: 2024
Journal Articles

A Single-Center Experience on the Safety and Efficacy of Venetoclax-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma

Eli Zolotov, Vanisha Patel, Yedidyah Weiss, Noa Biran, Pooja Phull, David H. Vesole, David S. Siegel, Harsh Parmar
Journal: Blood
Blood (2024) 144 (Supplement 1): 6959.
https://doi.org/10.1182/blood-2024-194740
Published: 2024
Journal Articles

MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma

H. Miles Prince, Nizar J. Bahlis, Paula Rodríguez-Otero, Lionel Karlin, Luke Akard, Asya Varshavsky-Yanovsky, Michael P. Chu, Yuya Nagai, David H. Vesole, Anne Hickman, Sharon T. Sullivan, Eric Leip, Umberto Conte, Andrea Viqueira, Alexander M. Lesokhin
Journal: Blood
Blood (2024) 144 (Supplement 1): 4738.
https://doi.org/10.1182/blood-2024-208192
Published: 2024
Journal Articles

Establishing a Distinct Cytokine Signature for Multiple Myeloma Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA)

Maher Albitar, Hong Zhang, Sally Agersborg, Ahmad Charifa, Pooja Phull, Noa Biran, David H. Vesole, Harsh Parmar, Andrew L Pecora, Andrew Ip, Andre Goy, David S. Siegel
Journal: Blood
Blood (2024) 144 (Supplement 1): 3316.
https://doi.org/10.1182/blood-2024-203774
Published: 2024
Journal Articles

Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

Behzad Amoozgar, Ayrton I Bangolo, David H. Vesole, David S. Siegel, Noa Biran, Pooja Phull, Michele L. Donato, Harsh Parmar
Journal: Blood
Blood (2024) 144 (Supplement 1): 2408.
https://doi.org/10.1182/blood-2024-211671
Published: 2024
Journal Articles

Enhanced Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma: Results from the Prommis Real-World Study

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T Mckay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Silvia D'Ambrosi, Rowan Kuiper, Martin H van Vliet, David S. Siegel, Saad Z. Usmani, Frits van Rhee
Journal: Blood
Blood (2024) 144 (Supplement 1): 1929.
https://doi.org/10.1182/blood-2024-209903
Published: 2024
Journal Articles

Clonotype-Naïve Detection of Clonality in Patients Suspected of Having Multiple Myeloma or Monoclonal Gammopathy Using Peripheral Blood Cell-Free RNA (cfRNA)

Maher Albitar, Hong Zhang, Sally Agersborg, Ahmad Charifa, Pooja Phull, Noa Biran, David H. Vesole, Harsh Parmar, Andrew L Pecora, Andrew Ip, Andre Goy, David S. Siegel
Journal: Blood
Blood (2024) 144 (Supplement 1): 1946.
https://doi.org/10.1182/blood-2024-201810
Published: 2024
Journal Articles

Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM)

David H. Vesole, Thomas G Martin, Suzanne Trudel, Henning Schade, Samantha Shenoy, Noa Biran, Jeffrey Lee Wolf, Jeffrey V Matous, Pamela Munster, Savannah Berkeley, Jesús G Berdeja
Journal: Blood
Blood (2024) 144 (Supplement 1): 1982.
https://doi.org/10.1182/blood-2024-209597
Published: 2024
Journal Articles

A Phase 2b Study of Selinexor in Combination with Carfilzomib, Daratumumab, or Pomalidomide in Patients with Multiple Myeloma Relapsing on Current Therapy

Noa Biran, David H. Vesole, Harsh Parmar, Pooja Phull, Kimberly Doucette, Rena Feinman, Joshua Zenreich, Palka Anand, Kristin Ivanovski, Monique Pace, Lisa Biamonte, Martha Campanaro, Trina McClendon, Chandani Limbad, Samanta BaboolallAracena, Adolfo Aleman, Rashmi Unawane, Elizabeth Pendergrass, Marie Layton, Genevieve Breeze, Aimee Chappell, Alexandra Della Pia, Susan Kumka, David S. Siegel
Journal: Blood
Blood (2023) 142 (Supplement 1): 6714.
https://doi.org/10.1182/blood-2023-187011
Published: 2023
Journal Articles

Sequential Administration of Selinexor and CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma

Sarvarinder Kaur Gill, Noa Biran, Pooja Phull, David H. Vesole, David S. Siegel, Harsh Parmar
Journal: Blood
Blood (2023) 142 (Supplement 1): 6930.
https://doi.org/10.1182/blood-2023-190413
Published: 2023
Journal Articles

Allogeneic (Allo-SCT) Versus Autologous Stem-Cell Transplantation (Auto-SCT) after Relapse to First Line Auto-SCT in Multiple Myeloma: A Meta-Analysis with Predominantly Individual Patient Data

Heinz Ludwig, Takashi Ikeda, Cesar O. Freytes, Koji Kawamura, Yoshiko Atsuta, Hiroyuki Takamatsu, David H. Vesole, Hari Parameswaran, Axel Hinke
Journal: Blood
Blood (2023) 142 (Supplement 1): 7100.
https://doi.org/10.1182/blood-2023-179105
Published: 2023
Journal Articles

Single-Center Experience of Carfilzomib-Based Combinations for Patients with Lymphoplasmacytic Lymphoma

Harsh Parmar, Noa Biran, Pooja Phull, David H. Vesole, David S. Siegel
Journal: Blood
Blood (2023) 142 (Supplement 1): 1684.
https://doi.org/10.1182/blood-2023-190155
Published: 2023
Journal Articles

Prommis Trial Prospectively Demonstrates the Efficacy of SKY92 Risk Stratification in Newly Diagnosed Multiple Myeloma Patients

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T. McKay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Lisette Stork-Sloots, Silvia D'Ambrosi, Rowan Kuiper, Martin van Vliet, David S. Siegel, Saad Z Usmani, Frits van Rhee
Journal: Blood
Blood (2023) 142 (Supplement 1): 3386.
https://doi.org/10.1182/blood-2023-180761
Published: 2023
Journal Articles

Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Prashant Kapoor, Don A. Stevens, Xavier Leleu, Karim Belhadj Merzoug, Lionel Karlin, Salomon Manier, Thomas Chalopin, Cyrille Hulin, Aurore Perrot, Jésus G Berdeja, Cristiana Costa Chase, Cyrille Touzeau, Philippe Moreau, Sanjay Mohan, Alexander Lesokhin, Carol Huff, David H. Vesole, Joshua Richter, Jeffrey Matous, Eileen Wolff, Tejas Shah, Jeppe Koch-Olsen, Andrew Garton, Vinu Menon, Sunitha Gn, Mario Perro, Eugene Zhukovsky, Cyril Konto, Lida Pacaud, Mohamad Mohty
Journal: Blood
Blood (2023) 142 (Supplement 1): 3339.
https://doi.org/10.1182/blood-2023-186664
Published: 2023
Journal Articles

Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T. McKay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Lisette Stork-Sloots, Silvia D'Ambrosi, Rowan Kuiper, Martin van Vliet, David S. Siegel, Saad Z Usmani, Frits van Rhee
Journal: Blood
Blood (2023) 142 (Supplement 1): 2013.
https://doi.org/10.1182/blood-2023-181905
Published: 2023
Journal Articles

A Phase 1/2 Study of Carfilzomib, Iberdomide and Dexamethasone (KID) in Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma

Noa Biran, David H. Vesole, Harsh Parmar, Pooja Phull, Kimberly Doucette, Rena Feinman, Joshua Zenreich, Palka Anand, Kristin Ivanovski, Monique Pace, Lisa Biamonte, Martha Campanaro, Trina McClendon, Chandani Limbad, Samanta BaboolallAracena, Adolfo Aleman, Rashmi Unawane, Elizabeth Pendergrass, Marie Layton, Genevieve Breeze, Aimee Chappell, Alexandra Della Pia, Susan Kumka, David S. Siegel
Journal: Blood
Blood (2023) 142 (Supplement 1): 2022.
https://doi.org/10.1182/blood-2023-189907
Published: 2023